https://doi.org/10.55788/c4720a65
“Comorbidity is important to our patients. We know that it is associated with higher disease activity, lower quality-of-life, and has a negative influence on treatment response,” said Dr Sizheng Steven Zhao (University of Manchester, UK) [1].
The current registry study aimed to explore whether a higher comorbidity burden also correlates with increased radiographic damage in patients with radiographic axSpA. Data was derived from the Australo-Anglo-American Spondyloarthritis Consortium (TASC). Comorbidity burden was quantified by counting 22 common conditions, including cardiovascular diseases (e.g. hypertension and heart failure), cancer, osteoporosis, and depression. Radiographs were evaluated using a modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) system.
“We divided the participants at baseline into 4 groups, those with no, 1, 2, or ≥3 comorbidities,” Dr Zhao said. Changes in mSASSS over time were related to the comorbidity count at baseline. Analyses were adjusted for the following baseline covariates: mSASSS, sex, symptom duration, C-reactive protein level, TNF inhibitor use, extra-musculoskeletal manifestations, and smoking status. The analysis included 1,150 participants, predominantly men (75%), with a mean age of 44 years, and a median follow-up of 2 years. Comorbidities were present in 73% of the cohort, with a median of 1 comorbidity per participant.
Radiographic progression (measured by mSASSS) was more pronounced with increasing comorbidity burden. Whereas those with 1 comorbidity showed no significant change in mSASSS (-0.2 units over 10 years), those with 2 comorbidities (2.7 units/10 years) and ³3 comorbidities (2.3 units/10 years) exhibited significant increases. This association was not driven by any specific comorbidity.
Thus, Dr Zhao concluded that comorbidity burden is independently associated with greater radiographic progression in axSpA. Moreover, comorbidity is also associated with higher baseline radiographic damage. Therefore, patients with a high comorbidity burden may benefit from targeted management. Future research should explore which conditions contribute most to the observed association and elucidate the underlying causal mechanisms.
- Zhao SS, et al. Comorbidity burden and radiographic progression in axial spondylarthritis. OP0103, EULAR 2024 Congress, 12–15 June, Vienna, Austria.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Hope for a durable effective injection therapy in knee osteoarthritis Next Article
Giant cell arteritis: Upadacitinib may be an upcoming treatment option »
« Hope for a durable effective injection therapy in knee osteoarthritis Next Article
Giant cell arteritis: Upadacitinib may be an upcoming treatment option »
Table of Contents: EULAR 2024
Featured articles
Advanced therapies show promising results in PsA real-world study
Small protein targeting IL-17A effective in PsA management
Late-breaking Abstracts
Nipocalimab meets primary endpoint in Sjögren’s syndrome
Advanced therapies show promising results in PsA real-world study
Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA
Small protein targeting IL-17A effective in PsA management
Spotlight on Rheumatoid Arthritis
New JAK1 inhibitor outperforms placebo in active RA
Macrophage profiling in synovial tissue predicts treatment response in RA
Innovative app boosts mental health in patients with RA
What is New in Lupus and Scleroderma
Daratumumab shows promise in systemic lupus erythematosus
Severe lung involvement in SSc linked to anti-Ro/SSA antibodies
Early treatment with ambrisentan might prevent PAH development in patients with SSc
Crystal-related Disorders in 2024
More patients hit their uric acid target with febuxostat and ruzinurad combination
Tophaceous gout at higher mortality risk than non-tophaceous gout
JAK Inhibition in Giant Cell Arteritis
Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?
Giant cell arteritis: Upadacitinib may be an upcoming treatment option
Spotlight on Other Indications
AxSpA: Higher comorbidity burden worsens radiographic progression
Hope for a durable effective injection therapy in knee osteoarthritis
Dermatomyositis: Triple therapy with tacrolimus beats cyclosporin regimen
Best of the Posters
Less fracture risk with denosumab than bisphosphonates in pre-treated osteoporosis
Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease
Stopping DMARDs? These key factors predict RA flares
Related Articles
January 14, 2022
More pros than cons for the use of statins in RA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com